179 related articles for article (PubMed ID: 20065058)
41. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
42. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
43. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
[TBL] [Abstract][Full Text] [Related]
44. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
45. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
46. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
47. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
[TBL] [Abstract][Full Text] [Related]
48. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
49. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Biedenbach DJ; Jones RN; Pfaller MA;
Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
[TBL] [Abstract][Full Text] [Related]
50. Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use.
Waites K; Rand K; Jenkins S; Yangco B; Brookings E; Gaskins D; Lewis J; Halkias K
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):181-9. PubMed ID: 7924211
[TBL] [Abstract][Full Text] [Related]
51. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
52. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
[TBL] [Abstract][Full Text] [Related]
53. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
[TBL] [Abstract][Full Text] [Related]
54. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
[TBL] [Abstract][Full Text] [Related]
55. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Neu HC; Labthavikul P
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
[TBL] [Abstract][Full Text] [Related]
56. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
57. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
Kocsis B; Domokos J; Szabo D
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
[TBL] [Abstract][Full Text] [Related]
58. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of moxifloxacin against local bacterial isolates.
Ling ML; Tan PL
Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.
Alcalá L; Cercenado E; García-Garrote F; Bouza E
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):27-31. PubMed ID: 9990472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
